SCHEMBL822762

SCHEMBL822762

Cn1nnnc1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.55
ALDH1A1 P00352 5/20 0.55
TSHR P16473 4/20 0.55
POLB P06746 1/20 0.53
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.50
LMNA P02545 1/20 0.49
HSD17B10 Q99714 1/20 0.49
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
NR1H2 P55055 1/20 0.47
NR1H3 Q13133 1/20 0.47
PTGS2 P35354 1/20 0.46
HSD11B1 P28845 1/20 0.46
ALOX15 P16050 1/20 0.45
ABCC9 O60706 1/20 0.44
ABCC8 Q09428 1/20 0.44
KCNJ11 Q14654 1/20 0.44
KCNJ8 Q15842 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7452483 0.87 ACLY (0.53) SMN1; SMN2ALDH1A1TSHRPOLBHTT
SCHEMBL22580263 0.85 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1TSHRPOLBHTT
SCHEMBL2318648 0.84 HPGDS (0.51) SMN1; SMN2ALDH1A1TSHRPOLBHTT
SCHEMBL5966721 0.83 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1TSHRHTTKMT2A
SCHEMBL12377870 0.82 L3MBTL1 (0.62) SMN1; SMN2ALDH1A1TSHRHTTKMT2A
SCHEMBL4604449 0.81 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1TSHRPOLBHTT
SCHEMBL22322904 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1POLBKMT2ALMNA
SCHEMBL3375138 0.79 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1HTTKMT2ALMNA
SCHEMBL420682 0.79 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1TSHRHTTKMT2A
SCHEMBL13028853 0.79 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1TSHRHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105814702-B Curable organosilicon composition and optical semiconductor device 道康宁东丽株式会社 2018-06-26 CN claimed
US-9691951-B2 Curable silicone composition, and optical semiconductor device DOW CORNING TORAY CO., LTD. (JP) 2017-06-27 US claimed
EP-3059768-A1 CURABLE SILICONE COMPOSITION, AND OPTICAL SEMICONDUCTOR DEVICE Dow Corning Toray Co., Ltd. (JP) 2016-08-24 EP claimed
US-20160233395-A1 Curable Silicone Composition, And Optical Semiconductor Device DOW TORAY CO., LTD. (JP) 2016-08-11 US claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
US-20240002355-A1 PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-01-04 US disclosed
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. 2023-10-12 US disclosed
EP-4248973-A2 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2023-09-27 EP disclosed
CN-116635372-A Novel process for producing tetrazole derivatives 豪夫迈·罗氏有限公司 2023-08-22 CN disclosed
WO-2022106669-A1 NEW PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2022-05-27 WO disclosed
WO-2021231615-A1 SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES EDGEWISE THERAPEUTICS, INC. (US) 2021-11-18 WO disclosed
EP-3227018-B1 CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS UNIV VIRGINIA COMMONWEALTH (US) 2021-06-30 EP disclosed
EP-0297042-A1 Substituted penem compounds CIBA-GEIGY AG (CH) 1988-12-28 EP disclosed
EP-0233155-A1 Aminoacyloxymethyl compounds CIBA-GEIGY AG (CH) 1987-08-19 EP disclosed
EP-0215739-A1 Synthesis of beta-lactam compounds CIBA-GEIGY AG (CH) 1987-03-25 EP disclosed
EP-0201459-A1 Acylaminomethyl-penem compounds, their preparation and pharmaceutical formulations containing them CIBA-GEIGY AG (CH) 1986-11-12 EP disclosed
EP-0132165-A1 Adsorbable alkynyl substituted heterocyclic quaternary ammonium salts and applications thereof to silver halide photography EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-01-23 EP disclosed
US-4471044-A Silver halide emulsions and photographic elements containing adsorbable alkynyl substituted heterocyclic quaternary ammonium salts EASTMAN KODAK COMPANY (US) 1984-09-11 US disclosed
US-4115122-A Internal latent image silver halide emulsion containing a heterocyclic quaternary salt having a propargyl or a butyryl containing substituent FUJI PHOTO FILM CO., LTD. (JP) 1978-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321091-A1 SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES IL6, MUSK, SMN1; SMN2 SMN1; SMN2 3/4885ALDH1A1 308/4885TSHR 3553/4885
US-20240002355-A1 PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES CYP2F1, CYP1A2, CYP3A4 SMN1; SMN2 2234/4885ALDH1A1 173/4885TSHR 162/4885
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 SMN1; SMN2 3894/4885ALDH1A1 2972/4885TSHR 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.